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Research on developmental pathways in model organisms provides key information on how to isolate,
maintain, and differentiate human pluripotent stem cells. However, details of developmental pathways differ
even across mammalian species. Full realization of the potential of stem cells will require more direct studies
of human or primate developmental biology.In the past decade, there have beenmajor
advances in our understanding of the
basic biology of stem cell self-renewal
and differentiation in many different
systems. One of the major drivers for this
growth has been the excitement about
the potential of stem cells for under-
standing and treating human disease.
Pluripotent stem cell research is the fast-
est rising area. This rise was fueled initially
by the derivation of human embryonic
stem (ES) cells and was accelerated
dramatically by the discovery that adult
somatic cells can be reprogrammed to
generate induced pluripotent stem (iPS)
cells. All of the work on the derivation,
induction, and differentiation of human
pluripotent stemcells is primarily informed
by studies in the mouse. Great strides
have been made in understanding the
basic developmental decisions that lead
from mouse zygote to blastocyst through
gastrulation to organogenesis (Rossant
and Tam, 2009). Many of these events
are controlled by pathways that are highly
conserved across vertebrates and inver-
tebrate systems. However, while overall
genetic modules and signaling networks
may be conserved, the order of their
temporal and spatial use is not always
the same in a mouse versus a frog or
a fly. Even among mammals, there are
clearly differences in developmental
details across different species. The
species that we need to understand the
best is the human, and yet early human
development is woefully understudied.
Will extrapolation from themouse be suffi-
cient to achieve the desired therapeutic
applications of human pluripotent stem
cell research? Here I discuss how devel-20 Developmental Cell 21, July 19, 2011 ª20opmental biology has enhanced stem
cell research and point to the challenges
ahead.
Understanding Pluripotency:
Mouse versus Human
Our understanding of the regulatory
networks that underlie the initiation and
maintenance of the pluripotent state has
expanded considerably based on both
focused genetic studies and genome-
wide analyses. Key transcription factors,
including Oct4, Sox2, and Nanog, act in
autoregulatory modules to specify the
pluripotent state in both mouse and
human. However, there is more than one
pluripotent state that can occur in the
embryo and that can be maintained
in vitro. In the mouse, at least three kinds
of pluripotent stem cell can be derived
from embryos: ES cells, epiblast stem
cells (EPI-SCs), and embryonic germ
(EG) cells (reviewed in Hanna et al.,
2010b) (Figure 1). ES cells derive from
the inner cell mass of the blastocyst and
can be maintained in defined conditions
in the presence of ERK and GSK3 inhibi-
tors in a so-called ‘‘naive’’ pluripotent
state (Nichols and Smith, 2011). EPI-SCs
were originally derived by explanting early
postimplantation epiblast, a tissue that
is still pluripotent but has moved away
from the naive state to be primed for
germ layer formation at gastrulation.
EPI-SCs differ from ES cells in their
growth factor requirements, their expres-
sion profiles, and their X-inactivation
status, but, like ES cells, they retain the
capacity to differentiate into multiple
cell types in vitro or in teratomas. ES cells
can be differentiated into EPI-SCs in vitro,11 Elsevier Inc.and, indeed, inner cell mass (ICM) cells
can give rise to EPI-SCs under the appro-
priate conditions (Najm et al., 2011).
Conversely, EPI-SCs can be reverted to
the naive state under certain conditions
(Hanna et al., 2010a). EG cells are derived
from culturing early primordial germ cells
and show many of the same properties
as ES cells in terms of differentiation and
chimera formation. EG cells have been
less well studied than ES and EPI-SCs,
and it is not really clear whether they
represent a truly distinct pluripotent cell
type. The recent discovery that pluripo-
tent stem cell lines can be derived directly
from PGCs by culture in 2i conditions rai-
ses the possibility that the naive pluripo-
tent state can be reached from either
a blastocyst or a germ cell starting point
(Nichols and Smith, 2011).
When human and mouse pluripotent
stem cells are compared, it becomes
clear that, while they share the funda-
mental property of pluripotency, they
differ in several other aspects, perhaps
related to differences in their embryonic
origins (Figure 1). ES-like cells have been
derived from human primordial germ cells
(Shamblott et al., 1998), but their exact
relationship to either the human ES cell
or the mouse EG cell is unclear. Human
ES cells, though derived from the blasto-
cyst, resemble mouse EPI-SCs rather
than ES cells in their molecular profile
and growth factor requirements. It has
not yet proven possible to derive stable
human stem cell lines with all the proper-
ties of the naive mouse ES state (Hanna
et al., 2010a). Is this a fundamental differ-
ence between mouse and human stem
cells and embryos, perhaps related to
Figure 1. Origins of Mouse and Human Pluripotent Cells
During early mouse development, the inner cell mass (ICM) of the blastocyst can generate ES cells, while
Epi-SCs can be derived from the epiblast of the early postimplantation embryo and from the blastocyst
ICM. In contrast, cells from the human ICM share properties of both ES cells and Epi-SCs, and true
Epi-SCs have not yet been derived from the human epiblast. At later stages, the PGCs of both mice
and humans can be used to generate pluripotent cells, although the relationship between mouse
EGCs, which can be converted into an ES cell-like state, and the EGC-like cells derived from humans
remains unclear. Finally, the adult cells of both mice and humans can be reprogrammed into pluripotent
iPSCs.
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naturally undergo a period of implanta-
tional delay, preserving the naive state?
We still have very limited knowledge of
the normal processes of human blasto-
cyst formation, implantation, and early
postimplantation development, even at
a descriptive level, let alone in the molec-
ular detail needed to compare and
contrast with the mouse. Experimental
access to early postimplantation human
material is not feasible, and nonhuman
primate embryology is an expensive
proposition. It is possible, with appro-
priate consent in some jurisdictions, to
obtain preimplantation human embryos
for study. However, there are no experi-
mental studies on the mechanisms of
lineage specification in humans andremarkably few studies even on the
expression patterns of known key regula-
tors. The little we do know suggests that
the timing of lineage separation between
the ICM and the trophectoderm may
occur later during blastocyst expansion
in the human versus the mouse. This is
largely based on the persistent expres-
sion of Oct4 in the trophectoderm of the
blastocyst until day 6 of development
(Chen et al., 2009). Even more extreme
temporal extension of Oct4 expression
in the trophectoderm lineage has been
seen in other mammalian species, such
as the cow and sheep. In the cow, exper-
imental cell transplant studies have
shown that, indeed, trophectoderm
lineage restriction does not occur until
after blastocyst expansion (Berg et al.,Developmental C2011). These differences in lineage timing
clearly have implications for the likely
properties of stem cells derived from
different mammalian blastocysts. Thus,
there is an urgent need to better under-
stand the fundamentals of human preim-
plantation embryo development.
Inducing Pluripotency
The greatest success in directly applying
mouse developmental discoveries to
human application in the past few years
has been in the area of induced pluripo-
tent stem cells. By exploring the transcrip-
tional network specific to the ICM and ES
cells, Shinya Yamanaka and colleagues
defined 24 factors that were candidates
to promote pluripotency. Using a combi-
natorial approach, they reduced this set
to four factors—Oct4, Sox2, Klf4, and
c-myc—that in combination could revert
mouse fibroblasts to an ES-like pheno-
type (Okita and Yamanaka, 2010). Impor-
tantly, exactly the same factors and
variations on these factors can reprogram
human adult cells to pluripotency (Okita
and Yamanaka, 2010). Thus, there clearly
is an underlying conservation in the plurip-
otent network across mammals. There
have been many subsequent studies
reducing or replacing this original set of
proteins, but the fundamental findings
still hold. Most improvements in reprog-
ramming have been performed first in
the mouse system and then transferred
to the human, usually with success.
However, we know that mouse and
human ES and iPS cells are not identical
in their overall genetic regulatory net-
works, as revealed by genome-scale
transcriptional profiling, ChIP-seq data
sets, proteomic interactions, and so forth
(Hanna et al., 2010b). It will be important
to continue to explore the underlying
fundamental modules of pluripotency if
we wish to impose pluripotency on any
cell type of interest. There are clearly still
many challenges ahead if iPS technology
is ever to be a robust system suited for cell
therapy.
Driving Differentiation
Whether pluripotent stem cells are to be
used to study disease in the Petri dish, to
test drug toxicity, or for direct patient-
based transplantation, differentiating the
cells into fully functional, mature cell types
that match their in vivo counterparts
remains a major challenge. Vertebrateell 21, July 19, 2011 ª2011 Elsevier Inc. 21
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increasing levels of insight into the
processes that control germ layer forma-
tion, induction of axial patterning, organ-
ogenesis, and lineage specification in
many different developing systems. This
accumulated knowledge has been ap-
plied successfully in many instances to
drive ES/iPS differentiation. For example,
the normal signaling interactions that drive
gastrulation can be replicated in vitro to
allow efficient formation of almost pure
definitive endoderm, mesoderm, and
neuroectoderm progenitors in vitro (Murry
and Keller, 2008). Replication of a more
complex series of developmental events
has successfully been applied to pro-
duce immature cardiomyocytes and
hepatocytes, fetal hematopoietic pro-
genitors, pancreatic beta cells, spinal
motor neurons, and dopamine-producing
neurons, among other cell types (Murry
and Keller, 2008). In most cases, where
studied, the protocols developed in
mouse can be translated in the human,
but the detailed time course and growth
factor conditions may differ.
Most of these protocols only generate
fetal-type cells, which is not surprising
since the starting point is an early
embryo-equivalent cell. Developmental
biology has made great strides in under-
standing early lineage development but
has provided less insight into the path-
ways that promote later maturation. There
clearly needs to be more crosstalk
between developmental biologists and
those studying postnatal physiology and
biochemistry of differentiated cells (such
as cardiomyocytes, hepatocytes, and
neurons) if we are to succeed in the goals
of stem cell therapeutic applications.
Later maturation and physiological func-
tion of human cells is likely to diverge
more markedly from the mouse than the
early lineage induction phases. This is an
area in which learning directly from human
physiology will be key.
But even if we can understand all
these phases from induction to matura-
tion, we still face major challenges in
being able to integrate these into simple,
short-term, cost-effective differentiation
protocols. Will complex three-dimen-
sional systems be needed to replicate
the tissue interactions in vivo? How
much can we short-circuit the normal
temporal progress of human develop-
ment to be able to generate postnatal22 Developmental Cell 21, July 19, 2011 ª20cells in vitro in less than 9 months? Do
we need to complete differentiation
in vitro or can progenitors be transplanted
in vivo to complete maturation there?
Directed Reprogramming
Human ES and iPS cells are very powerful
tools for studying human development
but are not necessarily the best starting
substrate for deriving mature adult
differentiated cells. A reasonable person
might ask, Why would anyone whose
goal was to produce adult cells for
therapy think it sensible to reprogram an
adult cell back to the beginning of devel-
opment and then ask it to recapitulate all
developmental steps again? Surely
a more sensible approach would be to
attempt to directly reprogram adult cells
to appropriate cell types? Building on
the early experiments of the myogenic
‘‘master regulators’’ by Hal Weintraub
(Weintraub, 1993) and buoyed by the
success of iPS reprogramming, there is
currently renewed excitement about the
possibility of reprogramming one adult
cell type to another. In the same way
that iPS reprogramming depended on
imposing the pluripotency transcription
factor (TF) network on a somatic cell,
a TF module for new adult cell specifica-
tion could be introduced into another
adult cell in order to change cell fate. For
example, transfection of 3–4 lineage-
specific TFs into fibroblasts in culture
has been reported to generate neural-
type (Vierbuchen et al., 2010) or cardio-
myocyte-type (Ieda et al., 2010) cells.
It is not surprising that transfection of
powerful transcription factors can change
cell behavior, but does it really generate a
complete lineage switch? The best exam-
ples to date of true lineage switching have
been between closely related lineages—
for example, lymphocyte to macrophage
or exocrine to endocrine pancreas—
where much of the regulatory network
is shared across the lineages. Directed
lineage reprogramming is likely to be
most successful in cases in which either
this condition applies or the starting cells
are in a relatively naive and open state.
Using the tools of iPS reprogramming to
open up the chromatin state of an adult
lineage and then imposing a specific
lineage pathway may be a viable method-
ology to redirect cell fate. Perhaps consis-
tent with this, transfection of Oct4 alone,
combined with a strong hematopoietic11 Elsevier Inc.cytokine selection strategy, was reported
to generate hematopoetic progenitors
from skin fibroblast populations (Szabo
et al., 2010). Similarly, transfection of the
four iPS TFs into fibroblasts, combined
with appropriate signaling inputs, has
been reported to generate neural pro-
genitors directly (Kim et al., 2011). Clearly
there is much more to be worked out
before ‘‘transdifferentiation’’ is robust.
However, the power of understanding
lineage development and applying that
knowledge to drive differentiation or
transdifferentiation cannot be denied.Conclusion
Stem cell biology is a subset of develop-
mental biology research that has the
potential to transform our understanding
and treatment of human disease. Only
by continuing to apply in vivo develop-
mental pathway analysis to the isolation,
expansion, and differentiation of stem
cells in vitro will we achieve the desired
therapeutic outcomes. Studies in model
organisms will continue to inform the
principles of lineage specification and
indicate prime candidate pathways, but
final robust human application will also
require more investment in direct stud-
ies of human or primate developmental
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